- YMAB Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Y-mAbs Therapeutics (YMAB) 8-K26 May 22Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary EndpointFinancial data
Company Profile